Nektar Therapeutics/NKTR

$1.61

-3.59%
-
1D1W1MYTD1YMAX

About Nektar Therapeutics

Nektar Therapeutics is a clinical-stage, research-based drug discovery biopharmaceutical company. The Company is focused on discovering and developing medicines in the field of immunotherapy. The Company has a research and development pipeline of investigational medicines in immunology and oncology. In oncology, it is focused on developing medicines based on targeting biological pathways that stimulate and sustain the body’s immune response to fight cancer. Its pipeline includes NKTR-255, Rezpegaldesleukin (REZPEG) and NKTR-0165. NKTR-255 is an investigational biologic that is designed to target the interleukin-15 (IL-15) pathway in order to activate the body’s innate and adaptive immunity. Its Rezpegaldesleukin pipeline is an investigational, potential first-in-class T regulatory cell stimulator that addresses this underlying immune system imbalance in people with many autoimmune and inflammatory conditions. Rezpegaldesleukin is being developed as a self-administered injection.

Ticker

NKTR

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Howard Robin

Employees

137

Headquarters

San francisco, United States

NKTR Metrics

BasicAdvanced
$306.64M
Market cap
-
P/E ratio
-$1.46
EPS
0.73
Beta
-
Dividend rate
$306.64M
0.72789
$1.75
$0.41
2.26M
6.45
6.136
-21.17%
-49.8%
-110.95%
-55.82%
3.403
2.44
2.341
-2.1%
26.08%
-16.16%

What the Analysts think about NKTR

Analyst Ratings

Majority rating from 4 analysts.
Hold

Price Targets

Average projection from 2 analysts.
24.22% upside
High $3.00
Low $1.00
$1.61
Current price
$2.00
Average price target

NKTR Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-176.47% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$23.8M
-1.24%
Net income
$-42M
-8.3%
Profit margin
-176.47%
-7.14%

NKTR Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 3.58%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.73
-$0.27
-$0.24
-$0.22
-
Expected
-$0.25
-$0.28
-$0.20
-$0.21
-$0.19
Surprise
189.03%
-4.89%
20.34%
3.58%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Nektar Therapeutics stock?

Nektar Therapeutics (NKTR) has a market cap of $306.64M as of April 15, 2024.

What is the P/E ratio for Nektar Therapeutics stock?

The price to earnings (P/E) ratio for Nektar Therapeutics (NKTR) stock is 0 as of April 15, 2024.

Does Nektar Therapeutics stock pay dividends?

No, Nektar Therapeutics (NKTR) stock does not pay dividends to its shareholders as of April 15, 2024.

When is the next Nektar Therapeutics dividend payment date?

Nektar Therapeutics (NKTR) stock does not pay dividends to its shareholders.

What is the beta indicator for Nektar Therapeutics?

Nektar Therapeutics (NKTR) has a beta rating of 0.73. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the Nektar Therapeutics stock price target?

The target price for Nektar Therapeutics (NKTR) stock is $2, which is 24.22% above the current price of $1.61. This is an average based on projections from 2 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Nektar Therapeutics stock

Buy or sell Nektar Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing